Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda constant 3 (IGLC3) encodes the constant region of the lambda light chain in human immunoglobulins (antibodies)[2][7]. Immunoglobulins are membrane-bound or secreted glycoproteins produced by B lymphocytes, and they mediate the humoral immune response by binding antigens, leading to elimination of pathogens. IGLC3 is predicted to enable antigen binding and participate in immunoglobulin-mediated immune responses[1][2][7]. The gene is expressed across various tissues and is a component of blood microparticles and extracellular exosomes[1][6]. IGLC3 is not itself a direct therapeutic target, receptor, or enzyme, but rather a structural part of antibodies, which are commonly exploited in therapy as whole molecules rather than as isolated constant regions[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda constant 3 (IGLC3).